Clinical trial
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women…
NCT00075270 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00075270 |
|---|---|
| Title | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer |
| Official title | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Paclitaxel, GW572016 (Lapatinib) |
| Enrollment | 580 |
| Start date | Jan 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Mar 1, 2012 |
| First posted | Jan 9, 2004 |
| Last update posted | May 6, 2015 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Germany, Hungary, Italy, Latvia and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: